A phase I trial of the pan-ERBB inhibitor neratinib combined with the MEK inhibitor trametinib in patients with advanced cancer with EGFR mutation/amplification, HER2 mutation/amplification, HER3/4 mutation or KRAS mutation

PURPOSE: Aberrant alterations of ERBB receptor tyrosine kinases lead to tumorigenesis. Single agent therapy targeting EGFR or HER2 has shown clinical successes, but drug resistance often develops due to aberrant or compensatory mechanisms. Herein, we sought to determine the feasibility and safety of...

Descripción completa

Detalles Bibliográficos
Autores principales: Piha-Paul, Sarina A., Tseng, Chieh, Tran, Hai T., Gao, Meng, Karp, Daniel D., Subbiah, Vivek, Tsimberidou, Apostolia Maria, Kawedia, Jitesh D., Fu, Siqing, Pant, Shubham, Yap, Timothy A., Morris, Van K., Kee, Bryan K., Blum Murphy, Mariela, Lim, JoAnn, Meric-Bernstam, Funda
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2023
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10326142/
https://www.ncbi.nlm.nih.gov/pubmed/37314501
http://dx.doi.org/10.1007/s00280-023-04545-4

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10326142/
https://www.ncbi.nlm.nih.gov/pubmed/37314501
http://dx.doi.org/10.1007/s00280-023-04545-4

Ejemplares similares